Peptide LexiconAll compounds

Enfuvirtide (Fuzeon, T-20): The 36-Amino-Acid Peptide That Was the First HIV Fusion Inhibitor — What It Is, What TORO 1 and TORO 2 Showed and Where It Stands

Enfuvirtide, also called T-20, is a synthetic 36-amino-acid peptide that blocks HIV-1 from fusing with and entering cells. Sold as Fuzeon from 2003 as a twice-daily injection for heavily treatment-experienced patients, it added about 0.8–0.9 log10 of viral-load reduction in the two TORO trials. Drugs@FDA now lists Fuzeon as discontinued.

FDA-approved 2003 (priority review)HIV-1 fusion inhibitorBrand Fuzeon listed as discontinued in the US

Caroline S · Published 2026-11-20

Length

36 amino acids; C204H301N51O64, molecular weight 4,492 (PubChem CID 16130199)

Sequence

Ac-YTSLIHSLIEESQNQQEKNEEELLELDKWASLWNWF-NH2 — N-acetylated, C-terminal amide (from PubChem's residue-by-residue description)

Origin

Synthetic. Fuzeon, Roche, NDA 021481, original approval 2003-03-13 under priority review (Drugs@FDA)

Last reviewed

2026-11-20

What is it good for?

Treating HIV-1 in people whose virus had become resistant to the older drug classes. It works outside the cell, stopping the virus's envelope from fusing with the cell membrane, so it was active against virus resistant to drugs that act inside the cell. It was added to an optimised background regimen and injected under the skin twice a day.

Illustration: A glass test tube half filled with deep green powder on a white bench.
Illustration

What it is

Enfuvirtide is a 36-amino-acid synthetic peptide that stops HIV-1 from merging with a human cell. PubChem lists it residue by residue — N-acetyl-tyrosine through to a C-terminal phenylalaninamide — with the formula C204H301N51O64 and a molecular weight of about 4,492. It was developed as T-20 and sold from 2003 as Fuzeon, the first drug of the class called fusion inhibitors.

Property Value Source
Length 36 amino acids PubChem description
Formula C204H301N51O64 PubChem CID 16130199
Molecular weight 4,492 PubChem
Ends N-acetyl; C-terminal amide PubChem
Route Subcutaneous, twice daily TORO 1 and TORO 2

How it acts. HIV-1 enters a cell by fusing its outer envelope with the cell membrane. The trial reports describe enfuvirtide as "a novel antiretroviral that blocks HIV-1 cell fusion and viral entry" (Lalezari 2003, Antivir Ther). Because it works at that first step, outside the cell, its activity did not depend on the enzymes that the older drug classes target — which is why it was tested in people whose virus resisted all three of those classes.

Other peptides in the library that act against microbes, such as the body's own defensins and the antibiotic daptomycin, are not HIV drugs; enfuvirtide is the library's only fusion inhibitor.

What the trials showed

Two randomised, open-label phase 3 trials ran in parallel. Both enrolled people with at least 5,000 copies of HIV-1 RNA per millilitre who had been treated with, or were resistant to, three classes of antiretroviral drugs, and both randomised 2:1 to enfuvirtide 90 mg twice daily plus an optimised background regimen, or the regimen alone.

24-week result TORO 1 (Americas) TORO 2 (Europe, Australia)
Patients randomised 501 512
Median baseline viral load 5.2 log10 copies/mL 5.1 log10 copies/mL
Median baseline CD4+ (enfuvirtide / control) 75.5 / 87.0 cells/mm³ 98.0 / 101.5 cells/mm³
Viral-load change, enfuvirtide −1.696 log10 −1.429 log10
Viral-load change, control −0.764 log10 −0.648 log10
CD4+ change (enfuvirtide / control) +76 / +32 +65.5 / +38.0

Both differences in viral load were significant (P < 0.001), and so were the CD4+ differences (P < 0.001 in TORO 1, P = 0.02 in TORO 2). A difference of 0.8 log10 means the viral load ended roughly six times lower than with the background regimen alone (10^0.8 ≈ 6.3). These patients had very low CD4+ counts at baseline — a population with few remaining options.

What is not established by these trials: any benefit in people new to treatment (the TORO trials enrolled only heavily treated patients), and outcomes beyond the 24-week primary analysis reported in these abstracts.

Risks the trials recorded

  • Injection-site reactions: reported by 98% of enfuvirtide patients in TORO 1; in a 48-week phase 2 study they occurred at least once in 68.5% of enfuvirtide-treated patients, mostly mild to moderate (PMID 14518696).
  • Pneumonia: TORO 1 recorded more cases of pneumonia with enfuvirtide than in the control group.
  • Burden: two subcutaneous injections a day on top of an oral regimen. A pharmacokinetic study found absorption comparable from abdomen, thigh and arm (relative bioavailability 101% and 117% against the abdomen), so sites could be rotated (PMID 12957192).

Where it stands

Drugs@FDA records Fuzeon under NDA 021481, held by Roche, with original approval on 13 March 2003 under priority review, and on 2026-11-20 listed the product as discontinued. Neither openFDA nor DailyMed held a current Fuzeon label that day, so this entry reports trial doses rather than label text, and does not state why or when sales ended. PubMed holds 1,076 records for enfuvirtide and ClinicalTrials.gov 54 studies.

Sources opened 2026-11-20: PubChem CID 16130199 (properties and description); Drugs@FDA record for NDA 021481; openFDA and DailyMed searches for a Fuzeon label (none current); Lalezari 2003, NEJM (TORO 1, PMID 12637625, abstract); Lazzarin 2003, NEJM (TORO 2, PMID 12773645, abstract); Lalezari 2003, Antivir Ther (PMID 14518696, abstract); Lalezari 2003, J Clin Virol (PMID 12957192, abstract); Lalezari 2003, AIDS Read (PMID 12765160, abstract); PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Lowers viral load when added to an optimised regimen in drug-resistant HIV-1

TORO 1 (NEJM 2003, PMID 12637625): 501 randomised; 24-week change −1.696 v −0.764 log10 copies/mL. TORO 2 (NEJM 2003, PMID 12773645): 512 randomised; −1.429 v −0.648, difference 0.781

Raises CD4+ cell counts compared with background therapy alone

TORO 1: +76 v +32 cells/mm³ (P < 0.001); TORO 2: +65.5 v +38.0 (P = 0.02)

Blocks HIV-1 cell fusion and viral entry

Mechanism as described in the trial reports (e.g. Lalezari 2003, Antivir Ther, PMID 14518696)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Fuzeon, NDA 021481 (Roche), approved 2003-03-13 under priority review; Drugs@FDA lists the product as discontinued (read 2026-11-20). openFDA and DailyMed held no current Fuzeon label on that date.

How it was given

90 mg by subcutaneous injection twice daily in the TORO trials, added to an optimised background regimen of three to five antiretroviral drugs.

Published record

PubMed: 1,076 records for 'enfuvirtide'; ClinicalTrials.gov: 54 studies (2026-11-20).

Frequently asked questions

What is enfuvirtide?

A synthetic 36-amino-acid peptide, also called T-20, that blocks HIV-1 from fusing with human cells. It was sold as Fuzeon and was the first drug of the fusion-inhibitor class.

How does enfuvirtide work?

The trial reports describe it as blocking HIV-1 cell fusion and viral entry. It acts at the cell surface rather than inside the cell, which is why it kept working against virus that had become resistant to the reverse-transcriptase and protease inhibitors.

What did the TORO trials show?

In two randomised phase 3 trials of about 1,000 heavily treated patients in total, adding enfuvirtide to an optimised regimen lowered viral load by roughly 0.8 to 0.9 log10 copies/mL more than the regimen alone at 24 weeks, and raised CD4+ counts more.

What dose was used?

90 mg injected under the skin twice daily in both TORO trials, alongside three to five other antiretroviral drugs. An earlier review reports that phase 2 work settled on 100 mg twice daily as the dose of choice; the trial reports give the 90 mg figure as the deliverable dose.

What were its main drawbacks?

Injection-site reactions, reported by 98% of enfuvirtide patients in TORO 1, and the need for two injections a day. TORO 1 also recorded more pneumonia in the enfuvirtide group than in controls.

Is Fuzeon still available?

Drugs@FDA lists the Fuzeon product as discontinued, and on 2026-11-20 neither openFDA nor DailyMed held a current Fuzeon label. This entry does not state why or when it was withdrawn from sale.